SCHEMBL594234

SCHEMBL594234

O=C(O)c1cccc(-n2cccc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC2 O75106 1/20 0.64
L3MBTL1 Q9Y468 6/20 0.58
ALDH1A1 P00352 4/20 0.58
HSD17B10 Q99714 4/20 0.58
KDM4E B2RXH2 3/20 0.58
HPGD P15428 3/20 0.58
POLB P06746 3/20 0.58
MAPT P10636 3/20 0.58
MEN1 O00255 2/20 0.58
GAA P10253 2/20 0.58
KMT2A Q03164 2/20 0.58
NR4A1 P22736 2/20 0.58
PTPN7 P35236 2/20 0.58
RECQL P46063 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
USP2 O75604 1/20 0.58
MYC P01106 1/20 0.58
HSPA1A P0DMV8 1/20 0.58
ALOX15 P16050 1/20 0.58
BLM P54132 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29671334 1.00 AOC2 (0.64) AOC2L3MBTL1ALDH1A1HSD17B10KDM4E
SCHEMBL3108140 0.84 AOC2 (0.69) AOC2L3MBTL1HSD17B10POLBMAPT
SCHEMBL27767836 0.82 AOC2 (0.62) AOC2L3MBTL1ALDH1A1HSD17B10KDM4E
SCHEMBL5813574 0.82 AOC2 (0.62) AOC2L3MBTL1ALDH1A1POLBMAPT
SCHEMBL7826352 0.81 KDM4E (0.48) AOC2L3MBTL1ALDH1A1HSD17B10KDM4E
SCHEMBL30481519 0.81 ALDH1A1 (0.54) L3MBTL1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL942202 0.81 ALDH1A1 (0.54) L3MBTL1ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL171098 0.80 ALDH1A1 (0.56) AOC2L3MBTL1ALDH1A1HSD17B10KDM4E
SCHEMBL29488338 0.79 IDO1 (0.61) CYP3A4
SCHEMBL939912 0.79 IDO1 (0.61) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107118773-A A kind of inorganic achirality quantum dot of gel load 国家纳米科学中心 2017-09-01 CN claimed
US-12391781-B2 Black particles, black coating material, coating film, and black matrix for color filters SEKISUI CHEMICAL CO., LTD. (JP) 2025-08-19 US disclosed
EP-4063426-B1 BLACK PARTICLES, BLACK COATING MATERIAL, COATING FILM, AND BLACK MATRIX FOR COLOR FILTERS SEKISUI CHEMICAL CO LTD (JP) 2025-06-18 EP disclosed
US-20250145578-A1 SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2025-05-08 US disclosed
EP-4157844-B1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER CENTRE NAT RECH SCIENT (FR) 2024-07-10 EP disclosed
CN-114502677-B Black particles, black paint, coating film, and black matrix for color filter 积水化学工业株式会社 2023-11-14 CN disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 US disclosed
US-20230312576-A1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER UNIVERSITÉ DE TOURS (FR) 2023-10-05 US disclosed
WO-2023158866-A2 SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2023-08-24 WO disclosed
WO-2023158866-A2 SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2023-08-24 WO disclosed
US-5824691-A CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-10-20 US disclosed
EP-0715624-B1 PROCESS FOR THE PREPARATION OF BENZODIAZEPINE COMPOUNDS USEFUL AS ANTAGONISTS OF CCK OR OF GASTRINE YAMANOUCHI PHARMA CO LTD (JP) 1998-04-08 EP disclosed
US-5728829-A MULTISTAGE REACTION OF N-PROTECTED BENZOTRIAZOLYL GLYCINE DERIVATIVE WITH AMINOKETONE, THEN REACTION WITH AMMONIA AND ACID CATALYZED CYCLIZATION FERRING-RESEARCH LIMITED (GB) 1998-03-17 US disclosed
EP-0784612-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP disclosed
CN-1129442-A Benzodiazepine * derivatives YAMANOUCHI PHARMA CO LTD (JP) 1996-08-21 CN disclosed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 WO disclosed
WO-1995006040-A1 BENZODIAZEPINE COMPOUNDS USEFUL AS ANTAGONISTS OF CCK OR OF GASTRINE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1995-03-02 WO disclosed
US-5234946-A Anticholesterol, antilipemic BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-10 US disclosed
EP-0395768-A1 SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE BANYU PHARMACEUTICAL CO., LTD. (JP) 1990-11-07 EP disclosed
US-4339457-A OF CYCLOPROPANECARBOXYLIC ACIDS, INSECTICIDES, MITICIDES FMC CORPORATION (US) 1982-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT AOC2 4160/4885L3MBTL1 3643/4885ALDH1A1 982/4885
US-20250145578-A1 SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS EIF2B3, EIF6, EIF2A AOC2 4710/4885L3MBTL1 347/4885ALDH1A1 4222/4885
US-20230312576-A1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER LIMK1, LIMK2, ROCK1 AOC2 4255/4885L3MBTL1 3922/4885ALDH1A1 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.